Australia's most trusted
source of pharma news
Tuesday, 15 July 2025
Posted 14 July 2025 AM
A twenty-year pharma veteran has taken the helm of a government-funded incubator for early-stage Australian companies investigating infectious diseases.
One of three incubators sharing in $100 million in Commonwealth funds, Biointelect Venturer will receive a $32.9 million grant to support companies innovating in the infectious disease space, specifically with vaccine and immune related therapies. Its run by strategic planning and commercialisation advisory firm Biointelect.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.